RPRX vs ZBH
Royalty Pharma plc vs Zimmer Biomet — AI-powered side-by-side comparison
RPRX
Royalty Pharma plc
56
Watch
VS
| Metric | RPRX | ZBH |
| AI Score |
56
|
69
|
| Price |
$57.79
|
$97.22
|
| P/E Ratio |
23.98×
|
23.54×
|
| ROE |
11.9%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.4%
|
69.9%
|
| Debt / Equity |
1.31×
|
0.59×
|
| Dividend Yield |
1.6%
|
1.0%
|
| RSI (14) |
49.6
|
63.1
|
| Beta |
0.425
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for RPRX versus ZBH.
ZBH leads by 13 points.
ZBH scores 69/100 (Buy) versus RPRX at 56/100 (Watch).
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical